Amarin Corporation plc reported an overview of new data relating to VASCEPA?/VAZKEPA (icosapent ethyl) presented at the American Heart Association Scientific Sessions 2021, which took place virtually from November 13-15, 2021. Rapid Fire Oral Session Presentation: ?Benefits of Icosapent Ethyl in Patients with Prior Peripheral Artery Disease: REDUCE-IT PAD,?? presented on behalf of all authors by Deepak L. Bhatt, M.D., M.P.H., Brigham and Women?s Hospital. Highlights: The investigators concluded that, ?Icosapent ethyl 4 g/day significantly reduced total (first and subsequent) primary endpoints by 32%, and trended toward a 22% reduction in first events, in patients with PAD. Icosapent ethyl provides substantial cardiovascular risk reduction in the high-risk REDUCE-IT population, with consistent benefits in patients with a history of PAD. Safety was generally consistent with the overall study. Overall tolerability and adverse events were generally similar between icosapent ethyl and placebo in patients with prior PAD. More atrial fibrillation/flutter occurred with icosapent ethyl versus placebo in patients with prior PAD (5.2% versus 2.6%, respectively; P=0.07). No differences in bleeding were observed between icosapent ethyl and placebo in patients with prior PAD, likely due to the sample size.? e-Poster Presentation: Eicosapentaenoic Acid (EPA) Restores Pulmonary Endothelial Nitric Oxide Bioavailability Following Exposure to Urban Air Pollution Small Particles?? presented on behalf of all authors by R. Preston Mason, Ph.D., Brigham and Women?s Hospital. Highlights: This study examined the effects of EPA on pulmonary endothelial cell (PEC) function and inflammatory state when challenged with air pollution particulate matter isolated from an urban environment. In this study, primary PECs were pre-treated with EPA (40 ?M) for two hours in 2% FBS-containing medium and then challenged with urban particulate matter (50 ?g/mL) for two hours. After two hours, media was washed out and HBSS buffer was added. Cells were then stimulated with a calcium ionophore and concurrent measurements of nitric oxide and ONOO- were performed using tandem electrochemical nanosensors. In parallel with the endothelial function analysis, soluble intracellular adhesion molecule-1 (sICAM-1) was detected. The study authors concluded that, ?EPA significantly improved pulmonary endothelial cell function under conditions of inflammation caused by air pollution particles, including reductions in nitroxidative stress and the soluble adhesion molecule ICAM-1. These effects of EPA in pulmonary tissue challenged with air particulate matter indicate a novel potential benefit for further exploration in people exposed to air pollution.? Late-Breaking Science Presentation: ?Icosapent Ethyl Versus Placebo In Outpatients With COVID-19: The Main Results Of PREPARE-IT 2? ? presented on behalf of all authors and the PREPARE-IT 2 Trial Investigators by Rafael Diaz, M.D., Estudios Cardiologicos Latinoamerica (ECLA), Rosario, Argentina. Highlights: These data represent the first presentation of the topline results from the PREPARE-IT 2 study, which was an investigator-initiated trial (IIT) to evaluate the efficacy of icosapent ethyl (IPE) to reduce hospitalizations or death in approximately 2000 patients in Argentina with a positive diagnosis for the COVID-19 virus. In this study, subjects were randomized 1:1 to receive IPE or placebo and received a loading dose of 8g per day of IPE for the first three days followed by 4g per day of IPE thereafter from days 4-28. The primary endpoint is COVID-19 related hospitalizations or death assessed through day 28. While the results of the PREPARE-IT 2 study in Argentina did not meet the primary and/or other endpoints studied, the company believe it is valuable for Amarin to support pilot IITs of this nature to determine the safety and potential efficacy of VASCEPA/VAZKEPA in a diverse group of at-risk populations. Importantly, the study supports the safety and tolerability of VASCEPA/VAZKEPA at varying doses. PREPARE-IT 1 and 2 are part of a series of IITs evaluating VASCEPA/VAZKEPA?s potential benefit in preventing and/or treating COVID-19. Amarin continues to support MITIGATE, another IIT study of IPE?s potential efficacy in the prevention of COVID-19. The results of this study have no relationship to or bearing on any approved indications for VASCEPA/VAZKEPA.